In short
A groundbreaking clinical trial is underway to assess the efficacy and safety of a new drug called RZ358, an anti-insulin receptor human monoclonal antibody, for treating congenital hyperinsulinism. This Phase 3 study aims to help patients who have not achieved adequate glycemic control with standard treatments. The trial focuses on reducing hypoglycemia events and improving overall blood glucose management in patients with this rare genetic condition.
At a glance
- Drug Name
- RZ358 (Anti-Insulin Receptor Human Monoclonal Antibody)
- Condition Treated
- Congenital Hyperinsulinism
- Trial Phase
- Phase 3
- Study Design
- Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm
- Primary Objective
- Assess glycemic efficacy by measuring hypoglycemia events over 24 weeks
- Key Eligibility Criteria
- Age 3 months to 45 years, diagnosed with congenital HI, inadequate control with standard therapies
- Treatment Arms
- 5 mg/kg RZ358, 10 mg/kg RZ358, Placebo (all with standard of care)
- Administration
- Intravenous infusion
- Study Duration
- 24-week pivotal period, followed by up to 2-year open-label extension
- Follow-up Period
- 8 weeks post-treatment
What is RZ358?
RZ358 is a new medication being studied for the treatment of congenital hyperinsulinism. It is also known as anti-(insulin receptor) human monoclonal antibody. This means it's a specially designed protein that targets and interacts with insulin receptors in the body.
What is Congenital Hyperinsulinism?
Congenital hyperinsulinism is a rare genetic condition where the body produces too much insulin. This leads to frequent episodes of low blood sugar (hypoglycemia), which can be dangerous if not managed properly. The condition is present from birth (congenital) and can be challenging to treat with current medications.
How RZ358 Works
RZ358 is designed to help manage blood sugar levels in people with congenital hyperinsulinism. It works by: Attaching to insulin receptors in the body Reducing the effect of excess insulin Helping to prevent dangerous drops in blood sugar This approach is different from other treatments that try to reduce insulin production.
Clinical Trial Details
A Phase 3 clinical trial is currently underway to evaluate the effectiveness and safety of RZ358. Here are some key details: The trial is randomized, double-blind, and placebo-controlled. This means participants are randomly assigned to receive either RZ358 or a placebo, and neither the participants nor the researchers know who is receiving which treatment. The study will last 24 weeks, with some participants potentially continuing treatment for up to 2 years. RZ358 is given as an intravenous infusion (through a vein) every 2 or 4 weeks. Two different doses are being tested: 5 mg/kg and 10 mg/kg. The main goal is to see if RZ358 can reduce the number of hypoglycemia events (low blood sugar episodes) compared to a placebo.
Eligibility Criteria
To participate in the trial, patients must meet certain criteria. Some key requirements include: Age: 3 months to 45 years old Diagnosed with congenital hyperinsulinism Experiencing at least 3 hypoglycemia events per week Not adequately controlled with current standard treatments There are also several exclusion criteria, such as recent major surgery, pregnancy, or certain medical conditions.
Potential Benefits
If successful, RZ358 could offer several benefits for patients with congenital hyperinsulinism: Reduced frequency of hypoglycemia events Improved blood sugar control Better quality of life with less need for frequent blood sugar monitoring and emergency treatments A new option for patients who don't respond well to current treatments
Safety Considerations
As with any new medication, safety is a top priority in the RZ358 clinical trial. Researchers will be closely monitoring: Side effects and adverse events Changes in laboratory tests Effects on the liver (through ultrasound scans) Any signs of high blood sugar (hyperglycemia) The body's immune response to the medication It's important to note that RZ358 is still being studied and is not yet approved for general use. The clinical trial will help determine if it's safe and effective for treating congenital hyperinsulinism.